Midostaurin (PKC412)

Catalog No.S8064 Synonyms: CGP 41251

Midostaurin (PKC412) Chemical Structure

Molecular Weight(MW): 570.64

Midostaurin (pkc412) is a multi-targeted kinase inhibitor, including PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50 ranging from 80-500 nM.

Size Price Stock Quantity  
USD 110 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 7 Publications

2 Customer Reviews

  • (f and g) Induction of apoptosis in HMC-1.1 and -1.2, respectively. Columns represent the mean of three independent experiments and the bars represent the standard error. ctrl, control; mido, midostaurin.

    Leukemia, 2018, 32(1):139-148. Midostaurin (PKC412) purchased from Selleck.

    PKC412 is cytotoxic to human HNSCC cells. The established HNSCC cells (SQ20B and SCC‐9 cell lines), primary human oral carcinoma cells (“Primary1/2”) and primary oral epithelial cells (“Epithelial”), were treated with indicated concentrations of PKC412. Cells were then cultured in complete medium for the applied time, and cell survival was tested by the MTT assay (a, d) and colony formation assay (c). Cell death was tested by the trypan blue staining assay (b). “CTR” indicates medium‐treated control group (for all figures). All the experiments were repeated five times, and similar results were obtained. n = 5 for each assay. Error bars indicate mean ± SD (for all figures). *p < 0.05 versus group “CTR.” HNSCC, head and neck squamous cell carcinoma; MTT, 3‐(4,5‐dimethyl‐thiazol-2-yl)2,5-diphenyl tetrazolium bromide; OD, optical density; PKC, protein kinase C

    J Cell Physiol, 2018, 233(12):9437-9446. Midostaurin (PKC412) purchased from Selleck.

Purity & Quality Control

Choose Selective PKC Inhibitors

Biological Activity

Description Midostaurin (pkc412) is a multi-targeted kinase inhibitor, including PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50 ranging from 80-500 nM.
Targets
PKCα [1]
(Cell-free assay)
PKCγ [1]
(Cell-free assay)
PKCβ1 [1]
(Cell-free assay)
PKCβ2 [1]
(Cell-free assay)
PPK [1]
(Cell-free assay)
22 nM 24 nM 30 nM 31 nM 38 nM
In vitro

Midostaurin(pkc412) is a broad spectrum protein kinase inhibitor. Midostaurin(pkc412) interacts strongly with ATP binding sites of the conventional PKC-α, -β and -γ, PDGFRβ, VEGF-R2, VEGF-R1 and the cyclin-dependant kinase 1-cyclin B complex. Midostaurin(pkc412) inhibits the growth of various human and animal cell lines in vitro at similar submicromolar concentrations. Midostaurin(pkc412) also effectively inhibits the in vitro proliferation of glioblastoma and induced the accumulation of cells in G2/M and formation of giant nuclei with extensive fragmentation and apoptotic bodies. Midostaurin(pkc412) is able to reverse the p-glycoprotein-mediated multidrug resistance of tumor cells in vitro. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human MV4-11 cells NFPmTXlEgXSxdH;4bYNqfHliYYPzZZk> M4q3VlczKGh? M2\UWmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1XPC1zMTDj[YxteyCjZoTldkA4OiCqcoOgZpkh[2WubDD0bZRmei2kbIXlJIF{e2G7LDDJR|UxRTF{IH7N M1T4R|E6PjV2NEC4
RS4-11 cells M3S4bGZ2dmO2aX;uJIF{e2G7 NELKbmQzKGh? MlLWTY5pcWKrdHnvckBw\iCITGSzJGlVTCCvdYThcpQh[XW2b4Doc5NxcG:{eXzheIlwdiCrbjDoeY1idiCUU{StNVEh[2WubIOgZYZ1\XJiMjDodpMh[nliZXzlZ5Rzd2OqZX3pcJVucW6nc3PlcoNmKGG|c3H5MEBKSzVyPUGzJI5O MYmxPVY2PDRyOB?=
CGTH-W-1 cell NXzp[nAzT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlzNTY5pcWKrdHnvckBw\iCqdX3hckBET1SKLWetNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQzNjZ3IN88US=> MWrTRW5ITVJ?
SW982 cell MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXX6e5hqUW6qaXLpeIlwdiCxZjDoeY1idiCVV{m4NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQ2NjV6IN88US=> MnTTV2FPT0WU
human EoL-1-cell cell NF7mXlBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHLoPFNKdmirYnn0bY9vKG:oIHj1cYFvKEWxTD2xMYNmdGxiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13Mj6wPEBvVQ>? NH3GXVFUSU6JRWK=
MOLM-13 cells MV3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NUnOfVZEPzJiaB?= NHnLTHZKdmirYnn0bY9vKG:oIF\MWFMhUVSGIHjleIVzd3q7Z3;1d{BufXSjboSgbY4hcHWvYX6gUW9NVS1zMzDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFczKGi{czDifUBOXFNiYYPzZZktKEeLNUC9NE4xPTVizszN MkK0NlYxQDFyMkO=
KASUMI-1 cell MUPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYD6R3VwUW6qaXLpeIlwdiCxZjDoeY1idiCNQWPVUWkuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwME[wNVYh|ryP MWDTRW5ITVJ?
NCI-H1755 cell NILvWpdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mn7DTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG3OVUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjB4MkezJO69VQ>? MX7TRW5ITVJ?
human MES-SA cell MXHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NUf0c45kUW6qaXLpeIlwdiCxZjDoeY1idiCPRWOtV2Eh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjB5NUS0JO69VQ>? Mn:2V2FPT0WU
human HCC1395 cell M3y3emdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{frWGlvcGmkaYTpc44hd2ZiaIXtZY4hUEOFMUO5OUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvODh2Mkig{txO M1rJWHNCVkeHUh?=
human D-336MG cell MVPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NV3wTZpOUW6qaXLpeIlwdiCxZjDoeY1idiCGLUOzOm1IKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5yOEe1OEDPxE1? MnraV2FPT0WU
CHP-212 cell NXfPfIxlT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFjwU4lKdmirYnn0bY9vKG:oIHj1cYFvKEOKUD2yNVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjB6N{ezJO69VQ>? M{\E[HNCVkeHUh?=
human KM12 cell NHLnepNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHz6OHlKdmirYnn0bY9vKG:oIHj1cYFvKEuPMUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlA6Ojd3IN88US=> NXX0fZhvW0GQR1XS
A204 cell M3TaUmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHPhUYtKdmirYnn0bY9vKG:oIHj1cYFvKEF{MESgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlExODV{IN88US=> MV3TRW5ITVJ?
CAL-51 cell Mk\US5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MX\Jcohq[mm2aX;uJI9nKGi3bXHuJGNCVC13MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVA4ODlizszN NV\WNIM{W0GQR1XS
human A431 cell NEfZOWNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MojETY5pcWKrdHnvckBw\iCqdX3hckBCPDNzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xNVIyPiEQvF2= NGD1[XdUSU6JRWK=
NCI-H650 cell M{\RZ2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmrYTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSE[1NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTF5MEig{txO M2LrWHNCVkeHUh?=
A427 cell Ml74S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWDJcohq[mm2aX;uJI9nKGi3bXHuJGE1OjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkGxPVE5KM7:TR?= MmryV2FPT0WU
human 769-P cell NUfpN|NkT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NELmSXVKdmirYnn0bY9vKG:oIHj1cYFvKDd4OT3QJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yOjB6MjFOwG0> NWTn[mp6W0GQR1XS
SW1710 cell M3m0WGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVrJcohq[mm2aX;uJI9nKGi3bXHuJHNYOTdzMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVM{OTZizszN M4SzOnNCVkeHUh?=
human H4 cell NYrEVJROT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVLyNZdnUW6qaXLpeIlwdiCxZjDoeY1idiCKNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVM6PjNizszN NF;2eZJUSU6JRWK=
HT-1080 cell NUT2NmpWT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NH\qfIpKdmirYnn0bY9vKG:oIHj1cYFvKEiWLUGwPFAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF3OUiyJO69VQ>? NGLCfXhUSU6JRWK=
human PANC-03-27 cell M1Pq[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGrkOJlKdmirYnn0bY9vKG:oIHj1cYFvKFCDTlOtNFMuOjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkG2NFIh|ryP NEjZbmdUSU6JRWK=
A375 cells MknjR5l1d3SxeHnjbZR6KGG|c3H5 M{\HUVczKGh? M4PSd3RwgGmlaYT5JIFo[Wmwc4SgbJVu[W5iQUO3OUBk\WyuczDh[pRmeiB5MjDodpMh[nliY3XscEB1cXSncj3icJVmKGG|c3H5MEBKSzVyPUCuNVgh|ryP NF;GU5QyQTZ3NESwPC=>
human HOP-62 cell Ml7CSpVv[3Srb36gZZN{[Xl? Mne3TY5pcWKrdHnvckBw\iCqdX3hckBJV1BvNkKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlE5ODd|IN88US=> MYPTRW5ITVJ?
human U031 cell NXHjO5R4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVzo[3ZzUW6qaXLpeIlwdiCxZjDoeY1idiCXMEOxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yQTZ7ODFOwG0> NWG2Vm9NW0GQR1XS
mouse BAF3 cells NWjHeWtZWHKxbHnm[ZJifGmxbjDhd5NigQ>? M{PpWmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlHGN{Bk\WyuczD0doFve2[xcn3l[EB4cXSqIGrOSlE6QC2IR1\SNUBkd26|dIL1Z5QtKEmFNUC9NE4zKM7:TR?= NIrsb24zOTl|NkW0Ni=>
human G-402 cell NEHjNFZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlWyTY5pcWKrdHnvckBw\iCqdX3hckBINTRyMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNlAzPTNizszN M1HQTHNCVkeHUh?=
human G-361 cell MV\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXvJcohq[mm2aX;uJI9nKGi3bXHuJGcuOzZzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6yNFg2OyEQvF2= MlqxV2FPT0WU
NCI-H810 cell NUPNeoYxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYHJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KOEGwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zOTB{NzFOwG0> MYrTRW5ITVJ?
NCI-H2030 cell NYHFOJdiT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXGxbmxbUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFIxOzBiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkKzNFA3KM7:TR?= NX[3eoI1W0GQR1XS
human HCT-116 cell M3f6R2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NEP2XnZKdmirYnn0bY9vKG:oIHj1cYFvKEiFVD2xNVYh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjJ|NU[4JO69VQ>? NInsb3FUSU6JRWK=
human SNU-423 cell NF\oU2tIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXPDbXhPUW6qaXLpeIlwdiCxZjDoeY1idiCVTmWtOFI{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5{M{[1O{DPxE1? NI\xfY9USU6JRWK=
human SCC-4 cell MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NUX0dW5IUW6qaXLpeIlwdiCxZjDoeY1idiCVQ1OtOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjN7Nkeg{txO NUfhXGVmW0GQR1XS
human SW48 cell MXjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NX;vUWNnUW6qaXLpeIlwdiCxZjDoeY1idiCVV{S4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zPjZ6IN88US=> NIKyPItUSU6JRWK=
human SF295 cell M1TqSWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mkf3TY5pcWKrdHnvckBw\iCqdX3hckBUTjJ7NTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNlczPTdizszN Mn\nV2FPT0WU
MDA-MB-231 cell Mkf5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWjJcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2yN|Eh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjJ6MUCxJO69VQ>? MUPTRW5ITVJ?
A172 cell M4H3dGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2Xk[WlvcGmkaYTpc44hd2ZiaIXtZY4hSTF5MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNlkyPSEQvF2= NVTyXod2W0GQR1XS
human BCPAP cell MmnSS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1vTb2lvcGmkaYTpc44hd2ZiaIXtZY4hSkOSQWCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlI6QDd7IN88US=> NUXMTpJVW0GQR1XS
human COLO-792 cell NYWzN|FUT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXHJcohq[mm2aX;uJI9nKGi3bXHuJGNQVE9vN{myJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zQTl5MjFOwG0> M4L0cnNCVkeHUh?=
human DU-145 cell MWfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NX:1TpdVUW6qaXLpeIlwdiCxZjDoeY1idiCGVT2xOFUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjNzOEi5JO69VQ>? M36ye3NCVkeHUh?=
NCI-H2122 cell MmLuS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MUnJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkGyNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzJ{OEWg{txO NISyUI5USU6JRWK=
human SK-UT-1 cell MVPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MX;Jcohq[mm2aX;uJI9nKGi3bXHuJHNMNVWWLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlMzQTV{IN88US=> NE\L[XBUSU6JRWK=
LXF-289 cell MkGwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYXJcohq[mm2aX;uJI9nKGi3bXHuJGxZTi1{OEmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlMzQTZ3IN88US=> MVHTRW5ITVJ?
human NCI-H1792 cell NVfO[2ZzT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MoLtTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG3PVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjN|MEm2JO69VQ>? NYXuem5FW0GQR1XS
MCF7 cell NU\lNG93T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHLvdHpKdmirYnn0bY9vKG:oIHj1cYFvKE2FRkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlM{Ojd2IN88US=> NHL2[3pUSU6JRWK=
HCT-15 cell NXXTXnY3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFjvfmxKdmirYnn0bY9vKG:oIHj1cYFvKEiFVD2xOUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzN2M{Kg{txO NXzVSHdKW0GQR1XS
human NCI-H358 cell M1;qbmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWTJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KM{W4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{OzV3MTFOwG0> NE[3WHBUSU6JRWK=
human HLE cell M1Hybmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1rZWmlvcGmkaYTpc44hd2ZiaIXtZY4hUEyHIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6zN|c2OiEQvF2= M4fLc3NCVkeHUh?=
human SW1088 cell M4G2UGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYTJcohq[mm2aX;uJI9nKGi3bXHuJHNYOTB6ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuN|M4QTdizszN NYjBWG5VW0GQR1XS
human K5 cell MlHYS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmCzTY5pcWKrdHnvckBw\iCqdX3hckBMPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwM{[xOFkh|ryP M2q2c3NCVkeHUh?=
human SR cell NFKyWmNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NUXPTWlZUW6qaXLpeIlwdiCxZjDoeY1idiCVUjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuN|Y2PzFizszN NYjLcYZTW0GQR1XS
human Calu-3 cell MmW5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MkP1TY5pcWKrdHnvckBw\iCqdX3hckBE[Wy3LUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlM3QDJ3IN88US=> NGrWOWNUSU6JRWK=
human SK-MEL-30 cell M1PFSmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYTJcohq[mm2aX;uJI9nKGi3bXHuJHNMNU2HTD2zNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzl7MUOg{txO M3;xbnNCVkeHUh?=
human SW780 cell NEjIdZJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NEjrNZVKdmirYnn0bY9vKG:oIHj1cYFvKFOZN{iwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE41OTF2MjFOwG0> MVLTRW5ITVJ?
NCI-H1563 cell M163cmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWHONXhOUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFE2PjNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkSxOFg1KM7:TR?= NES0bZFUSU6JRWK=
human MKN45 cell MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWLVRWJGUW6qaXLpeIlwdiCxZjDoeY1idiCPS160OUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPDF7M{Gg{txO NY\MR2g2W0GQR1XS
MDA-MB-157 cell NVWyeWFxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1HS[mlvcGmkaYTpc44hd2ZiaIXtZY4hVUSDLV3CMVE2PyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwNEKwNVUh|ryP NITUWoNUSU6JRWK=
human NCI-H522 cell NFX5NGpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{HnTGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi1NlIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjR{MzFOwG0> NEToN2hUSU6JRWK=
human A2780 cell MkDOS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MUnJcohq[mm2aX;uJI9nKGi3bXHuJGEzPzhyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD60O|UxOyEQvF2= MlH1V2FPT0WU
human A498 cell MX7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGfOeXlKdmirYnn0bY9vKG:oIHj1cYFvKEF2OUigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlQ4Pjl|IN88US=> MVHTRW5ITVJ?
human BxPC-3 cell MXLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWG4XWx5UW6qaXLpeIlwdiCxZjDoeY1idiCEeGDDMVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjR7M{[2JO69VQ>? NFzJUVhUSU6JRWK=
human A2058 cell NHK0NIRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1PtTWlvcGmkaYTpc44hd2ZiaIXtZY4hSTJyNUigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlUzQDR2IN88US=> M4\xd3NCVkeHUh?=
human PC-14 cell MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2e2U2lvcGmkaYTpc44hd2ZiaIXtZY4hWENvMUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlU{QDV3IN88US=> NXXjXlJKW0GQR1XS
human KG-1 cell NFHQ[41Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mn61TY5pcWKrdHnvckBw\iCqdX3hckBMTy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD61OVQyQSEQvF2= M1jhdnNCVkeHUh?=
human A375 cell MlrOS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFK3e2pKdmirYnn0bY9vKG:oIHj1cYFvKEF|N{WgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlU3OTB|IN88US=> M2DwWXNCVkeHUh?=
human SW1783 cell NHzXfndIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1LCcmlvcGmkaYTpc44hd2ZiaIXtZY4hW1dzN{izJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE44OzN5IN88US=> NWTkbXh5W0GQR1XS
human MKN1 cell M17VTGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mny3TY5pcWKrdHnvckBw\iCqdX3hckBOU05zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD64PFQyOiEQvF2= NUn6cnBXW0GQR1XS
NCI-H1650 cell NFPtb29Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MUfJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMU[1NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvQDh7MUdjhKDPxE1? NYHMXIhoW0GQR1XS
human HT-1376 cell MnXqS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVnRfYNJUW6qaXLpeIlwdiCxZjDoeY1idiCKVD2xN|c3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC57MkmxPEDPxE1? NYnGZYdxW0GQR1XS
SW872 cell MVvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NH7XdJNKdmirYnn0bY9vKG:oIHj1cYFvKFOZOEeyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE46PDR3OTFOwG0> M134[XNCVkeHUh?=
human RT-112 cell NEfZNmdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlmxTY5pcWKrdHnvckBw\iCqdX3hckBTXC1zMUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlk4PDh|IN88US=> NH6zd5NUSU6JRWK=
human HT-29 cell MoC4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGnES|RKdmirYnn0bY9vKG:oIHj1cYFvKEiWLUK5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE46Pzl7NjFOwG0> MkTrV2FPT0WU
human U-266 cell NEDIPGtIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWXJcohq[mm2aX;uJI9nKGi3bXHuJHUuOjZ4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD65PFMxOiEQvF2= NEnSZ|NUSU6JRWK=
human HEL cell NH\6enFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFfpXFNKdmirYnn0bY9vKG:oIHj1cYFvKEiHTDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuPVg2OTdizszN MmTZV2FPT0WU
human KU812 cell MXnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHL5WmVKdmirYnn0bY9vKG:oIHj1cYFvKEuXOEGyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4yOTF4NDFOwG0> NXLLV4hTW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo Midostaurin(pkc412) may suppress tumor growth by inhibiting tumor angiogenesis (via its effects on the VEGF receptor tyrosine kinases) in addition to directly inhibiting tumor cell proliferation (via its effects on PKCs). This anti-angiogenic action may contribute to the antimetastatic and broad antitumor activity displayed by midostaurin(pkc412), as well as the synergy with cytotoxic agents, including doxorubicin, cyclophosphamide, cisplatin and gemcitabine. When given orally, the maximally tolerated dose for midostaurin(pkc412) is >300 mg/kg. [1]

Protocol

Cell Research:[2]
+ Expand
  • Cell lines: A549, NCI-H520
  • Concentrations: ~1.0 μM
  • Incubation Time: 24-72 h
  • Method: Each well is added with 5 mM WST-1 and 0.2 mM 1-methoxy PMS and the absorbance at 450 nm is measured by a Microplate Reader.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Colo 205 colorectal tumors xenograft
  • Formulation: sterile water
  • Dosages: 50 mg/kg, 200 mg/kg, once daily
  • Administration: p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (175.24 mM)
Ethanol 20 mg/mL warmed (35.04 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+45% PEG 300+ddH2O
For best results, use promptly after mixing.
4mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 570.64
Formula

C35H30N4O4

CAS No. 120685-11-2
Storage powder
in solvent
Synonyms CGP 41251

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03836209 Not yet recruiting Acute Myeloid Leukemia PrECOG LLC.|Astellas Pharma Inc July 2019 Phase 2
NCT03836209 Not yet recruiting Acute Myeloid Leukemia PrECOG LLC.|Astellas Pharma Inc July 2019 Phase 2
NCT03760445 Not yet recruiting Leukemia Myeloid Acute Novartis Pharmaceuticals|Novartis February 28 2019 Phase 1|Phase 2
NCT03760445 Not yet recruiting Leukemia Myeloid Acute Novartis Pharmaceuticals|Novartis February 28 2019 Phase 1|Phase 2
NCT03591510 Not yet recruiting FLT3-mutated Acute Myeloid Leukemia Novartis Pharmaceuticals|Novartis December 28 2018 Phase 2
NCT03591510 Not yet recruiting FLT3-mutated Acute Myeloid Leukemia Novartis Pharmaceuticals|Novartis December 28 2018 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PKC Signaling Pathway Map

Related PKC Products0

Tags: buy Midostaurin (PKC412) | Midostaurin (PKC412) supplier | purchase Midostaurin (PKC412) | Midostaurin (PKC412) cost | Midostaurin (PKC412) manufacturer | order Midostaurin (PKC412) | Midostaurin (PKC412) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID